Use of AD Informer Set compounds to explore validity of novel targets in Alzheimer's disease pathology.

ABSTRACT:

Introduction

A chemogenomic set of small molecules with annotated activities and implicated roles in Alzheimer's disease (AD) called the AD Informer Set was recently developed and made available to the AD research community: https://treatad.org/data-tools/ad-informer-set/.

Methods

Small subsets of AD Informer Set compounds were selected for AD-relevant profiling. Nine compounds targeting proteins expressed by six AD-implicated genes prioritized for study by Target Enablement to Accelerate Therapy Development for Alzheimer's Disease (TREAT-AD) teams were selected for G-protein coupled receptor (GPCR), amyloid beta (Aβ) and tau, and pharmacokinetic (PK) studies. Four non-overlapping compounds were analyzed in microglial cytotoxicity and phagocytosis assays.

Results

The

SUBMITTER: Potjewyd FM 

PROVIDER: S-EPMC9005681 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature